Dataset Information

Lymphedema alters lipolytic, lipogenic, immune and angiogenic properties of adipose tissue: a hypothesis-generating study in breast cancer survivors.

ABSTRACT: Later stages of secondary lymphedema are associated with the massive deposition of adipose tissue (AT). The factors driving lymphedema-associated AT (LAT) expansion in humans remain rather elusive. We hypothesized that LAT expansion could be based on alterations of metabolic, adipogenic, immune and/or angiogenic qualities of AT. AT samples were acquired from upper limbs of 11 women with unilateral breast cancer-related lymphedema and 11 healthy women without lymphedema. Additional control group of 11 female breast cancer survivors without lymphedema was used to assess systemic effects of lymphedema. AT was analysed for adipocyte size, lipolysis, angiogenesis, secretion of cytokines, immune and stem cell content and mRNA gene expression. Further, adipose precursors were isolated and tested for their proliferative and adipogenic capacity. The effect of undrained LAT- derived fluid on adipogenesis was also examined. Lymphedema did not have apparent systemic effect on metabolism and cytokine levels, but it was linked with higher lymphocyte numbers and altered levels of several miRNAs in blood. LAT showed higher basal lipolysis, (lymph)angiogenic capacity and secretion of inflammatory cytokines when compared to healthy AT. LAT contained more activated CD4+ T lymphocytes than healthy AT. mRNA levels of (lymph)angiogenic markers were deregulated in LAT and correlated with markers of lipolysis. In vitro, adipose cells derived from LAT did not differ in their proliferative, adipogenic, lipogenic and lipolytic potential from cells derived from healthy AT. Nevertheless, exposition of preadipocytes to LAT-derived fluid improved their adipogenic conversion when compared with the effect of serum. This study presents results of first complex analysis of LAT from upper limb of breast cancer survivors. Identified LAT alterations indicate a possible link between (lymph)angiogenesis and lipolysis. In addition, our in vitro results imply that AT expansion in lymphedema could be driven partially by exposition of adipose precursors to undrained LAT-derived fluid.

SUBMITTER: Koc M

PROVIDER: S-EPMC8046998 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Similar Datasets

Project description:A major challenge in realizing regenerative treatment using freshly isolated Adipose Derived Regenerative Cells (ADRCs) is the cellular heterogeneity and donor variability. Ex vivo expanded ADRCs (=ASCs) are available at larger quantities and represent a more homogeneous population suitable for allogenic use. Emerging pre-clinical and clinical data however suggest similar, or even superior efficacy of ADRCs as compared to ASCs for indications involving (micro)vascular deficiency. Since CD31+ ADRCs lack in cultured ASCs, we hypothesized that these cells account for improvement of vascular function in the heterogenous ADRCs. Herein, we found that in patients with erectile dysfunction (ED), the number of injected CD31+ ADRCs correlates positively with erectile function 12 months after one bolus of autologous ADRCs. Comprehensive in vitro and ex vivo analyses confirmed superior pro-angiogenic and paracrine effects of human CD31+ enriched ADRCs compared to the corresponding CD31- and parent ADRCs. CD31+, CD31- and ADRCs were co-cultured in aortic ring-, as well as in ED-relevant corpus cavernousum tube formation assays, both showing a significantly higher ability of the CD31+ ADRCs to support tube development. This effect was corroborated using conditioned medium (CM), while quantitative mass spectrometric analysis suggested that this is explained by secretory pro-angiogenic proteins such as DKK3, ANGPT2, ANAX2 and VIM, all being enriched in CD31+ADRC CM. To gain further specification of the ADRC subpopulations expressing these proteins, single-cell RNA sequencing was performed and showed that transcripts of the upregulated and secreted proteins were present in 9 endothelial ADRC subsets including endothelial progenitor cells in the heterogenous non-cultured ADRCs. Our data thus suggest that the vascular benefit of using ADRCs in regenerative medicine is dictated by CD31+ ADRCs, which likely represent an improved alternative to heterogenous ADRCs as well as ASCs when aiming for vascular repair in cell therapy.

Project description:Historically, several different approaches have been applied to explain the metabolic cost of uphill human running. Most of these approaches result in unrealistically high values for the efficiency of performing vertical work during running uphill, or are only valid for running up steep inclines. The purpose of this study was to reexamine the metabolic cost of uphill running, based upon our understanding of level running energetics and ground reaction forces during uphill running. In contrast to the vertical efficiency approach, we propose that during incline running at a certain velocity, the forces (and hence metabolic energy) required for braking and propelling the body mass parallel to the running surface are less than during level running. Based on this idea, we propose that the metabolic rate during uphill running can be predicted by a model, which posits that (1) the metabolic cost of perpendicular bouncing remains the same as during level running, (2) the metabolic cost of running parallel to the running surface decreases with incline, (3) the delta efficiency of producing mechanical power to lift the COM vertically is constant, independent of incline and running velocity, and (4) the costs of leg and arm swing do not change with incline. To test this approach, we collected ground reaction force (GRF) data for eight runners who ran thirty 30-second trials (velocity: 2.0-3.0 m/s; incline: 0-9°). We also measured the metabolic rates of eight different runners for 17, 7-minute trials (velocity: 2.0-3.0 m/s; incline: 0-8°). During uphill running, parallel braking GRF approached zero for the 9° incline trials. Thus, we modeled the metabolic cost of parallel running as exponentially decreasing with incline. With that assumption, best-fit parameters for the metabolic rate data indicate that the efficiency of producing mechanical power to lift the center of mass vertically was independent of incline and running velocity, with a value of ?29%. The metabolic cost of uphill running is not simply equal to the sum of the cost of level running and the cost of performing work to lift the body mass against gravity. Rather, it reflects a constant cost of perpendicular bouncing, decreased costs of parallel braking and propulsion and of course the cost of lifting body mass against gravity.

Dataset Information

Lymphedema alters lipolytic, lipogenic, immune and angiogenic properties of adipose tissue: a hypothesis-generating study in breast cancer survivors.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets